Form 4 for ELVN Enliven Therapeutics, Inc.

Accepted 2025-04-23 00:00:00 ET · period of report 2025-04-21 · accession 0001415889-25-011213 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2025-04-23	2025-04-21	ELVN	Lyssikatos Joseph P	CSO	S - Sale	$16.08	-5,000	998.0K	-0.5%	-$80.4K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-04-21	S	D	330	$16.72	997,688	I See footnote	—	—	(F4) This transaction was executed in multiple trades at prices ranging from $16.63 to $16.745. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
2	Common	Common Stock	2025-04-21	S	D	4,670	$16.03	998,018	I See footnote	—	—	(F2) This transaction was executed in multiple trades at prices ranging from $15.43 to $16.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.